coadministered cagrilintide and semaglutide in adults with overweight or obesity New the August 14, 2025, issue of NEJM: Cagrilintide–Semaglutide for (REDEFINE 1 phase 3a trial) https://nej.md/444aW7f Cagrilintide–Semaglutide for Overweight Diabetes (REDEFINE 2 phase 3a trial) https://nej.md/4ehQwLk Order Cagrilintide 5mg+Semaglutide 5mg |

Glutathione IV is a medical intervention where a high dose of glutathione, the main antioxidant in the body is intravenously dripped into the bloodstream

Dis Model Mech

Current anesthesia care guidance for diabetic patients taking GLP-1 agonists Lets examine the 2023 consensus-based practice guidelines published by the ASA regarding the anesthetic considerations of the GLP-1RAs: GLP-1 agonists are associated with many adverse effects, such as nausea, vomiting, delayed gastric emptying, and abdominal pain and bloating

Microglia-endothelial cross-talk regulates diabetes-induced retinal vascular dysfunction through remodeling inflammatory microenvironment

However, intense or prolonged workouts may increase hunger signals temporarily due to energy depletion